JP2023510872A5 - - Google Patents
Info
- Publication number
- JP2023510872A5 JP2023510872A5 JP2022542899A JP2022542899A JP2023510872A5 JP 2023510872 A5 JP2023510872 A5 JP 2023510872A5 JP 2022542899 A JP2022542899 A JP 2022542899A JP 2022542899 A JP2022542899 A JP 2022542899A JP 2023510872 A5 JP2023510872 A5 JP 2023510872A5
- Authority
- JP
- Japan
- Prior art keywords
- molecules
- manipulated
- gene
- mhc
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960607P | 2020-01-13 | 2020-01-13 | |
| US202062960617P | 2020-01-13 | 2020-01-13 | |
| US62/960,607 | 2020-01-13 | ||
| US62/960,617 | 2020-01-13 | ||
| PCT/US2021/013140 WO2021146222A1 (en) | 2020-01-13 | 2021-01-12 | Modification of blood type antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510872A JP2023510872A (ja) | 2023-03-15 |
| JP2023510872A5 true JP2023510872A5 (https=) | 2024-01-22 |
| JP7853210B2 JP7853210B2 (ja) | 2026-04-28 |
Family
ID=74562041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542899A Active JP7853210B2 (ja) | 2020-01-13 | 2021-01-12 | 血液型抗原の修飾 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230272429A1 (https=) |
| EP (1) | EP4090743A1 (https=) |
| JP (1) | JP7853210B2 (https=) |
| CN (1) | CN116234906A (https=) |
| AU (1) | AU2021207810A1 (https=) |
| CA (1) | CA3164591A1 (https=) |
| WO (1) | WO2021146222A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| US12221622B2 (en) | 2019-05-10 | 2025-02-11 | The Regents Of The University Of California | Modified pluripotent cells |
| BR112023024231A2 (pt) * | 2021-05-19 | 2024-01-30 | Sana Biotechnology Inc | Células t primárias rhd negativas hipoimunogênicas |
| US20240358761A1 (en) | 2021-08-11 | 2024-10-31 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| EP4384598A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| US20250129346A1 (en) * | 2021-08-11 | 2025-04-24 | Sana Biotechnology, Inc. | Engineering cells for cell-based therapies, and associated compositions and methods |
| AU2022325232A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| WO2025117331A1 (en) | 2023-12-01 | 2025-06-05 | Eli Lilly And Company | Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same |
| CN118291605A (zh) * | 2024-04-10 | 2024-07-05 | 深圳市血液中心(深圳市输血医学研究所) | 一种基于ngs的多系统红细胞血型基因分型方法和试剂盒 |
| CN118638907A (zh) * | 2024-06-26 | 2024-09-13 | 中国人民解放军联勤保障部队第九六〇医院 | 一种用于检测易漏检类孟买表型的snp标记 |
| CN119913243A (zh) * | 2025-04-01 | 2025-05-02 | 浙江省血液中心 | Abo血型变异体的snp位点、b亚型变异型血型鉴定试剂盒和方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| EP2840140B2 (en) | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| IL239344B2 (en) | 2012-12-12 | 2024-06-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| WO2017194699A1 (en) * | 2016-05-13 | 2017-11-16 | University Of Copenhagen | A cell-based array platform |
| JP2020505025A (ja) * | 2017-01-13 | 2020-02-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫工学的な改変をした多能性細胞 |
| IL270835B2 (en) | 2017-06-12 | 2025-01-01 | Sinai Health Sys | Allograft tolerance without the need for systemic immunosuppression |
| WO2019084531A1 (en) * | 2017-10-27 | 2019-05-02 | The Children's Hospital Of Philadelphia | MODIFIED RED GLOBES HAVING PHENOTYPES OF RARE ANTIGENS |
| WO2020018620A1 (en) * | 2018-07-17 | 2020-01-23 | The Regents Of The University Of California | Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells |
| CA3109078A1 (en) * | 2018-07-17 | 2020-01-23 | The Regents Of The University Of California | Cells differentiated from immunoengineered pluripotent cells |
| US11162079B2 (en) * | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| US12221622B2 (en) * | 2019-05-10 | 2025-02-11 | The Regents Of The University Of California | Modified pluripotent cells |
-
2021
- 2021-01-12 WO PCT/US2021/013140 patent/WO2021146222A1/en not_active Ceased
- 2021-01-12 US US17/792,121 patent/US20230272429A1/en active Pending
- 2021-01-12 AU AU2021207810A patent/AU2021207810A1/en active Pending
- 2021-01-12 JP JP2022542899A patent/JP7853210B2/ja active Active
- 2021-01-12 EP EP21704098.9A patent/EP4090743A1/en active Pending
- 2021-01-12 CN CN202180022172.7A patent/CN116234906A/zh active Pending
- 2021-01-12 CA CA3164591A patent/CA3164591A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510872A5 (https=) | ||
| Lanza et al. | Engineering universal cells that evade immune detection | |
| Gornalusse et al. | HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells | |
| JP2022543112A5 (https=) | ||
| JP2024144548A (ja) | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 | |
| JP6816031B2 (ja) | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 | |
| Schirmbeck et al. | The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens | |
| Kohn et al. | New frontiers in the therapy of primary immunodeficiency: from gene addition to gene editing | |
| JP2023002716A (ja) | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 | |
| Patel et al. | T-cell therapies for HIV: preclinical successes and current clinical strategies | |
| US9228007B1 (en) | Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells | |
| CN114072516A (zh) | 经修饰的腺病毒 | |
| JP2024532772A5 (https=) | ||
| JP7523357B2 (ja) | ウイルスベクター産生 | |
| JP2015506365A (ja) | Ｃｄ４＋ｔ細胞応答を向上するための修飾されたエピトープ | |
| CN108474003A (zh) | 包含微小rna识别元件的cmv载体 | |
| Levesque et al. | CRISPR-based therapeutic genome editing for inherited blood disorders | |
| Cervantes-Barragan et al. | Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity | |
| Kleinstiver et al. | 731. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects | |
| Sii-Felice et al. | Innovative Therapies for Hemoglobin Disorders: K. Sii-Felice et al. | |
| Vanniasinkam et al. | DNA immunization using a non-viral promoter | |
| Sheppard et al. | Vaccination against endogenous retrotransposable element consensus sequences does not protect rhesus macaques from SIVsmE660 infection and replication | |
| AU2020370254B2 (en) | Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice | |
| Porteus | Knock-in editing: it functionally corrects! | |
| JP7714667B2 (ja) | 改変ヒト人工多能性幹細胞の製造方法 |